Format

Send to

Choose Destination
Vaccine. 2013 Oct 17;31(44):5009-14. doi: 10.1016/j.vaccine.2013.08.086. Epub 2013 Sep 8.

Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.

Author information

1
Department of Clinical Research, U. S. Army Medical Research of Infectious Diseases (USAMRIID), Fort Detrick, MD, USA. Electronic address: phillip.r.pittman.civ@mail.mil.

Abstract

We describe the Bacillus anthracis protective antigen IgG antibody response and the B. anthracis lethal toxin neutralization activity to a delayed dose of anthrax vaccine adsorbed (AVA, BioThrax(®)) using validated assays. 373 individuals received 1, 2, or 3 priming doses, 18-24 months afterward, they received a delayed dose of AVA. Overall, 23.6% of subjects showed detectable anti-PA IgG before the boost, compared to 99.2% (P<0.0001) 28 days after the boost. Geometric mean anti-PA IgG concentration (GMC) was 1.66 μg/mL before and 887.82 μg/mL after the boost (P<0.0001). The proportion of individuals with four-fold increase in GMC following the boost ranged from 93.8% to 100%. Robust anti-PA IgG levels and B. anthracis lethal toxin neutralization activity are induced when an AVA dose is delayed as long as two years. These data support continuing with the vaccination schedule when a dose is delayed as long as two years rather than restarting the series.

KEYWORDS:

AVA; BioThrax(®) anthrax vaccine adsorbed; Human antibody response to anthrax vaccine

PMID:
24026013
DOI:
10.1016/j.vaccine.2013.08.086
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center